

Resource Summary Report

Generated by PRECISE-TBI on Sep 7, 2026

NCGC Pharmaceutical Collection

RRID:SCR_006909

Type: Tool

Proper Citation

NCGC Pharmaceutical Collection (RRID:SCR_006909)

Resource Information

URL: <http://tripod.nih.gov/npc/>

Proper Citation: NCGC Pharmaceutical Collection (RRID:SCR_006909)

Description: The NCGC Pharmaceutical Collection (NPC) is a comprehensive, publically-accessible collection of approved and investigational drugs for high-throughput screening that provides a valuable resource for both validating new models of disease and better understanding the molecular basis of disease pathology and intervention. The NPC has already generated several useful probes for studying a diverse cross section of biology, including novel targets and pathways. NCGC provides access to its set of approved drugs and bioactives through the Therapeutics for Rare and Neglected Diseases (TRND) program and as part of the compound collection for the Tox21 initiative, a collaborative effort for toxicity screening among several government agencies including the US Environmental Protection Agency (EPA), the National Toxicology Program (NTP), the US Food and Drugs Administration (FDA), and the NCGC. Of the nearly 2750 small molecular entities (MEs) that have been approved for clinical use by US (FDA), EU (EMA), Japanese (NHI), and Canadian (HC) authorities and that are amenable to HTS screening, we currently possess 2,400 as part of our screening collection. The NPC resource currently consists of (i) the physical collection suitable for high throughput screening (HTS) and (ii) the informatics browser and database. Putting together the physical collection has been surprisingly challenging in terms of the time and effort required in the informatics, compound management and synthetic chemistry related activities required for this endeavor. We provide access to the NPC screening library through collaboration. Please contact our Scientific Director Dr. Chris Austin for additional information. The other half of the NPC resource is the NPC browser. This is a self-contained software that is actively developed and maintained by the informatics group to provide electronic access to the NPC content. The latest version of the NPC browser for various platforms can be downloaded.

Abbreviations: NPC

Synonyms: The NCGC Pharmaceutical Collection, National Center for Advancing Translational Sciences Pharmaceutical Collection, NIH Chemical Genomics Center Pharmaceutical Collection, National Institutes of Health Chemical Genomics Center Pharmaceutical Collection, NCATS Pharmaceutical Collection

Resource Type: material resource, reagent supplier

Defining Citation: [PMID:21525397](#)

Keywords: drug, disease, high-throughput screening, molecule, molecular entity, compound, small molecule

Funding: NHGRI

Resource Name: NCGC Pharmaceutical Collection

Resource ID: SCR_006909

Alternate IDs: nlx_144647

Record Creation Time: 20220129T080238+0000

Record Last Update: 20260905T133042+0000

Ratings and Alerts

No rating or validation information has been found for NCGC Pharmaceutical Collection.

No alerts have been found for NCGC Pharmaceutical Collection.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Kumar R, et al. (2019) Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work. European journal of medicinal chemistry, 182, 111602.

Zhang L, et al. (2015) Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget, 6(11), 9073.

Giubellino A, et al. (2014) High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma. PloS one, 9(4), e90458.

Shen M, et al. (2013) Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs. PLoS one, 8(9), e75252.

Nilubol N, et al. (2012) Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening. Journal of translational medicine, 10, 198.